EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optogenetic screening of MCT1 activity implicates a cluster of non-steroidal anti-inflammatory drugs (NSAIDs) as inhibitors of lactate transport

Scott A Wegner, Hahn Kim, José L Avalos iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0312492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Scott A Wegner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America. Hauptthemen laut MEDLINE: Monocarboxylic Acid Transporters, Anti-Inflammatory Agents, Non-Steroidal, Symporters. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Princeton University, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lactate transport plays a crucial role in the metabolism, microenvironment, and survival of cancer cells. However, current drugs targeting either MCT1 or MCT4, which traditionally mediate lactate import or efflux respectively, show limited efficacy beyond in vitro models. This limitation partly arises from the existence of both isoforms in certain tumors, however existing high-affinity MCT1/4 inhibitors are years away from human testing. Therefore, we conducted an optogenetic drug screen in Saccharomyces cerevisiae on a subset of the FDA-approved drug library to identify existing scaffolds that could be repurposed as monocarboxylate transporter (MCT) inhibitors. Our findings show that several existing drug classes inhibit MCT1 activity, including non-steroidal estrogens, non-steroidal anti-inflammatory drugs (NSAIDs), and natural products (in total representing approximately 1% of the total library, 78 out of 6400), with a moderate affinity (IC 50 1.8–21 μM). Given the well-tolerated nature of NSAIDs, and their known anticancer properties associated with COX inhibition, we chose to further investigate their MCT1 inhibition profile. The majority of NSAIDs in our screen cluster into a single large structural grouping. Moreover, this group is predominantly comprised of FDA-approved NSAIDs, with seven exhibiting moderate MCT1 inhibition. Since these molecules form a distinct structural cluster with known NSAID MCT4 inhibitors, such as diclofenac, ketoprofen, and indomethacin, we hypothesize that these newly identified inhibitors may also inhibit both transporters. Consequently, NSAIDs as a class, and piroxicam specifically (IC 50 4.4 μM), demonstrate MCT1 inhibition at theoretically relevant human dosages, suggesting immediate potential for standalone MCT inhibition or combined anticancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monocarboxylic Acid TransportersAnti-Inflammatory Agents, Non-SteroidalSymportersHumansOptogeneticsSaccharomyces cerevisiaeBiological TransportLactic AcidDrug Evaluation, PreclinicalMonocarboxylate Transport Protein 1

Substanzen

Monocarboxylic Acid TransportersAnti-Inflammatory Agents, Non-SteroidalSymportersLactic AcidMonocarboxylate Transport Protein 1

Autor:innen und Institutionen

  • Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
  • Department of Chemistry, Princeton University, Princeton, New Jersey, United States of America.
  • Princeton University Small Molecule Screening Center, Princeton University, Princeton, New Jersey, United States of America.
  • Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey, United States of America.
  • The Andlinger Center for Energy and the Environment, Princeton University, Princeton, New Jersey, United States of America.
  • High Meadows Environmental Institute, Princeton University, Princeton, New Jersey, United States of America.

ORCID-Profile: José L Avalos

Förderung

  • NIGMS NIH HHS
  • Princeton University
  • National Institute of General Medical Sciences

Zitieren

APA

Wegner, S. A., Kim, H., & Avalos, J. L. (2024). Optogenetic screening of MCT1 activity implicates a cluster of non-steroidal anti-inflammatory drugs (NSAIDs) as inhibitors of lactate transport. PLOS ONE. https://doi.org/10.1371/journal.pone.0312492

Vancouver

Wegner SA, Kim H, Avalos JL. Optogenetic screening of MCT1 activity implicates a cluster of non-steroidal anti-inflammatory drugs (NSAIDs) as inhibitors of lactate transport. PLOS ONE. 2024. doi:10.1371/journal.pone.0312492

BibTeX
@article{Wegner2024,
  author = {Wegner, Scott A and Kim, Hahn and Avalos, José L},
  title = {Optogenetic screening of MCT1 activity implicates a cluster of non-steroidal anti-inflammatory drugs (NSAIDs) as inhibitors of lactate transport},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0312492}
}
Kostenlos starten →